Conventional Medical Management of Ulcerative Colitis: Tacrolimus

Baumgart, Daniel C.

doi:10.1007/978-1-4614-0998-4_40

Cited by 5 publications

(10 citation statements)

References 73 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Introductionmentioning

confidence: 99%

“…Crohn's disease (CD) is a chronic, primarily gastrointestinal, inflammatory disease that results from a combination of genetic and environmental factors 5 . One known environmental factor that can increase the risk of CD is tobacco use 5 . Meta‐analyses published in 1989 and 2006 both found significant associations between smoking and the risk of CD (OR 1.8 and 2.0, respectively) 6,7 .…”

Section: Introductionmentioning

confidence: 99%

“…5 One known environmental factor that can increase the risk of CD is tobacco use. 5 Metaanalyses published in 1989 and 2006 both found significant associations between smoking and the risk of CD (OR 1.8 and 2.0, respectively). 6,7 Moreover, smoking is associated with an increased risk of surgery, need for immunosuppressive medications, and relapse.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Tobacco use in Crohn's disease patients and association with disease outcomes in the United States Medicaid population, 2010–2019

et al. 2023

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Tobacco use in Crohn's disease patients and association with disease outcomes in the United States Medicaid population, 2010–2019

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), are chronic relapsing conditions characterized by abdominal pain, diarrhea with mucus and/or blood, weight loss, and extraintestinal symptoms such as arthritis or uveitis 1. The incidence in most western countries is over 6.38 per 1000 person-years, making this debilitating disease one of the most common autoimmune diseases 2,3.…”

mentioning

confidence: 99%

“…The incidence in most western countries is over 6.38 per 1000 person-years, making this debilitating disease one of the most common autoimmune diseases 2,3. A cure remains elusive but IBD can be managed with medications that induce and maintain remission, including corticosteroids, 5-aminosalicylic acid, methotrexate, thiopurines, and the now well-established biologicals 1,4. However, with a loss-of-response rate of 30% to 40%, these conventional therapies are not completely effective in all patients 5.…”

mentioning

confidence: 99%

A Systematic Review With Meta-Analysis of the Efficacy of Cannabis and Cannabinoids for Inflammatory Bowel Disease

Doeve¹,

Meeberg

Schaik³

et al. 2020

Journal of Clinical Gastroenterology

View full text Add to dashboard Cite

Goal and Background: A number of studies have investigated the effectiveness of cannabis or cannabinoids for treatment of inflammatory bowel diseases (IBD). We aimed to systematically analyze their effect in in the treatment of IBD patients. Study: We included randomized controlled trials and nonrandomized studies analyzing IBD patients of any age using cannabi(noid)s. Two reviewers searched 3 databases until August 13, 2019. Primary outcome was clinical remission and secondary outcomes included inflammatory biomarkers, symptom improvement, quality of life (QoL) scores, and hospital outcomes. Risk of bias was assessed according to study type. The meta-analyses were performed using a random-effects model with subgroup analyses based on study type. Results: The search identified 682 records of which 15 nonrandomized studies and 5 randomized controlled trials were eligible for inclusion. The meta-analysis of the primary outcome included 146 randomized participants, all 18 years of age or older. Risk of bias was moderate. Cannabi(noid)s were not effective at inducing remission (risk ratio=1.56, 95% confidence interval=0.99-2.46). No effect on inflammatory biomarkers was observed. However, clinical symptoms (abdominal pain, general well-being, nausea, diarrhea, and poor appetite) all improved with cannabi(noid)s on Likert-scales. Baseline QoL scores were lower in patients using cannabis among cohort studies but improved significantly with cannabi(noid)s. Although length of hospital stay was shorter and risk of parenteral nutrition was lower in patients using cannabis, there was no effect on other IBD complications. Conclusions: Cannabi(noid)s do not induce clinical remission or affect inflammation in IBD patients. However, cannabi(noid)s significantly improve patient-reported symptoms and QoL.

show abstract

Immunological aspects of determination of an adequate biological treatment sequence for inflammatory bowel diseases: the expert board statement (St. Petersburg, May 22, 2021)

Белоусова

Kozlov²,

Абдулганиева

et al. 2021

Alʹm. klin. med.

View full text Add to dashboard Cite

On May 22, 2021, the Expert Board met in St. Petersburg to discuss their position on immunological aspects of determination of an adequate biological treatment sequence for inflammatory bowel diseases (IBD). The Expert Board aimed at discussion of current strategies, development of a consensus on determination of an adequate biological treatment sequence for IBD. The main topics of the agenda were the contribution of immune system to the pathophysiology of Crohn's disease, ulcerative colitis and their complications, efficacy of genetically engineered biological agents (GEBA) at various stages of IBD management. Participation of the leading Russian experts in IBD, as well as involvement of other specialties, made it possible to consider the topic by a multidisciplinary team, with an in-depth analysis of IBD pathophysiology, to better understand the course of the disease in some contradictory situation, for instance, when clinical remission is not associated with an endoscopically confirmed remission. One of the expected effects of this Expert Board meeting would be an improvement of GEBA administration in clinical practice, mostly due to the modification of clinical guidelines. This would ascertain and confirm the algorithms for GEBA administration for IBD, including the optimal treatment sequence depending on an agent’s mechanism of action and the patient profile. The clarification of the optimal GEBA sequence in the clinical guidelines could lead to more frequent GEBA administration in local medical clinics and institutions in the regions, where GEBA are used insufficiently due to little experience and absence of their precise positioning in the clinical guidelines.

show abstract

Conventional Medical Management of Ulcerative Colitis: Tacrolimus

Cited by 5 publications

References 73 publications

Tobacco use in Crohn's disease patients and association with disease outcomes in the United States Medicaid population, 2010–2019

Tobacco use in Crohn's disease patients and association with disease outcomes in the United States Medicaid population, 2010–2019

A Systematic Review With Meta-Analysis of the Efficacy of Cannabis and Cannabinoids for Inflammatory Bowel Disease

Immunological aspects of determination of an adequate biological treatment sequence for inflammatory bowel diseases: the expert board statement (St. Petersburg, May 22, 2021)

Contact Info

Product

Resources

About